1.
Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late.
Hepat Mon. 2008; 8(3) : 165
-9
[PubMed]
2.
Alavian SM. Hepatitis C infection in Iran; A review article.
Iran J Clin Infect Dis. 2009; 4(1) : 47
-59
3.
Alter MJ. Epidemiology of hepatitis C virus infection.
World J Gastroenterol. 2007; 13(17) : 2436
-41
[PubMed]
4.
Brown RSJr, Gaglio PJ. Scope of worldwide hepatitis C problem.
Liver Transpl. 2003; 9(11) -3
[PubMed]
5.
Alavian SM,
Lankarani KB,
Alaei-Andabili SH,
Pouryasin A,
Ebrahimi Daryani N,
Nassiri Toosi M,
et al.
Treatment of chronic hepatitis C Infection: Updated of the Recommendation from Scientific Leaders' Meeting-28th July 2011-tehran, IR iRAN.
Hepat Mon. 2011; 11(9) : 703
-13
6.
Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review.
Hepat Mon. 2009; 9(3) : 211
-23
7.
Merat S,
Rezvan H,
Nouraie M,
Jafari E,
Abolghasemi H,
Radmard AR,
et al.
Seroprevalence of hepatitis C virus: the first population-based study from Iran.
Int J Infect Dis. 2010; 14 Suppl 3 -6
[PubMed]
8.
Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection.
Arch Iran Med. 2005; 8(2) : 84
-90
9.
Williams R. Global challenges in liver disease.
Hepatology. 2006; 44(3) : 521
-6
[PubMed]
10.
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma.
Hepatology. 1997; 26(3) : 34S
-8S
[PubMed]
11.
El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model.
Eur J Health Econ. 2005; 6(2) : 159
-65
[PubMed]
12.
Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN.
Gastro Hepat. 2010; 3(1) : 5
-14
13.
Lavanchy D. The global burden of hepatitis C.
Liver Int. 2009; 29 Suppl 1 : 74
-81
[PubMed]
14.
Kanwal F,
Farid M,
Martin P,
Chen G,
Gralnek IM,
Dulai GS,
et al.
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
Am J Gastroenterol. 2006; 101(9) : 2076
-89
[PubMed]
15.
Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C.
Arch Intern Med. 2001; 161(18) : 2231
-7
[PubMed]
16.
Dienstag JL, Isselbacher KJ. Harrison's principles of internal medicine. 2005;
17.
Kenneth W, Lin MD, Jeffrey T, Kirchner DO. Lancaster, American Family Physicisn.
Pennsylvania. 2004; 69 : 75
-82
18.
Rice DP. Cost of illness studies: what is good about them?
Inj Pre. 2000; 6(3) : 175
-6
19.
Berenguer J,
Alvarez-Pellicer J,
Martin PM,
Lopez-Aldeguer J,
Von-Wichmann MA,
Quereda C,
et al.
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Hepatology. 2009; 50(2) : 407
-13
[PubMed]
20.
Singal AK,
Singh A,
Jaganmohan S,
Guturu P,
Mummadi R,
Kuo YF,
et al.
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Clin Gastroenterol Hepatol. 2010; 8(2) : 192
-9
[PubMed]
21.
Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes.
Hepat Mon. 2003; 5(3) : 77
-82
22.
Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a AND alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis.
BMC Infect Dis. 2012; 12(1) : 357
[PubMed]
23.
Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
Hepatology. 2000; 31(1) : 211
-8
[PubMed]
24.
Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C.
Lancet. 2003; 362(9401) : 2095
-100
[PubMed]
25.
Fried MW,
Shiffman ML,
Reddy KR,
Smith C,
Marinos G,
Goncales FL, Jr.,
et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med. 2002; 347(13) : 975
-82
[PubMed]
26.
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C.
Hepatology. 2004; 39(4) : 1147
-71
[PubMed]
27.
Center for Disease Control and Prevention. Cost analysis: Introduction/CDC Econ Eval Tutorials.
28.
Moghimi-Dehkordi B,
Vahedi M,
Khoshkrood Mansoori B,
Kasaeian A,
Safaee A,
Habibi M,
et al.
Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study.
Arab J Gastroenterol. 2011; 12(2) : 86
-9
[PubMed]
29.
Moghimi-Dehkordi B,
Vahedi M,
Pourhoseingholi MA,
Khoshkrood Mansoori B,
Safaee A,
Habibi M,
et al.
Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study.
J Dig Dis. 2011; 12(5) : 384
-92
[PubMed]
30.
Mohaghegh Shalmani H,
Soori H,
Khoshkrood Mansoori B,
Vahedi M,
Moghimi-Dehkordi B,
Pourhoseingholi MA,
et al.
Direct and indirect medical costs of functional constipation: a population-based study.
Int J Colorectal Dis. 2011; 26(4) : 515
-22
[PubMed]
31.
Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran.
Int J Colorectal Dis. 2007; 22(7) : 791
-9
[PubMed]
32.
Medical Laws and Tariffs. [The price list by Iranian Cabinet of the Public Health Centers]. 2010;
33.
Iranian Ministry of Health and Medical Education. [List of price of drugs]. 2010;
34.
Trading Economic Website. 2010;
35.
Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study.
Hepat Mon. 2009; 9(2) : 95
-102
[PubMed]
36.
Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection.
Ther Adv Chronic Dis. 2011; 2(1) : 39
-45
[PubMed]
37.
Iranian Databases of Census Publication. 2006;
LEAVE A COMMENT HERE: